Medisafe 1 Technologies Pre-pays Convertible Promissory Note Due in Full to Avoid Dilution to Shareholders

JERUSALEM, June 7, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has pre-paid a $45,000 convertible promissory note incurred on October 15 2010, including the interest due, on May 9, 2011.

The note beared interest at 8% per annum and was due on July 15, 2011. The note had conversion rights allowing the holder of the note at any time to convert all or any part of the remaining principal balance into the Company's common stock at a price equal to 58% of the average of the lowest three trading prices for the Common Stock during the most recent ten-day period.

The note was issued to fund development of Medisafe 1's patented life-saving technology and to assist in ongoing business development.

As a result of pre-payment, the non-affiliated third party lender has released Medisafe 1 Technologies from its obligation.

"Medisafe 1 pre-paid the promissory note to prevent the note from being converted into equity," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "Pre-payment of the note prevented the dilution of our common stock."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

    Contact:

    Jacob Elhadad
    CEO
    +972-524440000
    [email protected]

SOURCE Medisafe 1 Technologies Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED